PDCD1 and head and neck squamous cell carcinoma: One phase II trial examining a combination therapy for R/M HNSCC using EGFR inhibition as well as PD-1 inhibition has also shown encouraging results, with a 45% overall response rate at 6 months with a relatively favorable side effect profile.